Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

NEXT STORY
Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions
PREV STORY
ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

author_avatar
NASDAQ Market News

Lyme Disease (LD): Global Market Insights, Epidemiology and Forecast to 2027

Dublin, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The "Lyme Disease (LD)- Market Insights, Epidemiology ...

author_avatar
NASDAQ Market News

Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

author_avatar
NASDAQ Market News